Ovarian teratomas represent a significant portion of germ cell neoplasms encountered in clinical practice. While most of these tumors are mature and benign, the presence of immature elements changes the clinical landscape drastically for both surgeons and patients. In a notable recent case, a 29-year-old female presented with sudden, severe pelvic pain, raising immediate concern for acute ovarian torsion. Initial imaging studies supported this suspicion by identifying a large adnexal mass. However, emergency surgical intervention revealed a more complex and concerning scenario: a ruptured 130 mm ovarian mass with signs of peritoneal contamination. Subsequent histopathological analysis identified a mixed teratoma, with 25% of the tissue containing high-grade (Grade 3) immature neuroectodermal elements. This finding classified the malignancy as FIGO Stage IC2. Clinicians must recognize that **immature ovarian teratoma management** involves much more than just addressing the immediate surgical crisis. It requires a high index of oncological suspicion and a comprehensive multidisciplinary approach to ensure survival. Consequently, early detection and precise pathological grading are paramount in these rare cases. This specific case highlights how a standard gynecological emergency can mask an underlying high-grade malignancy. Therefore, surgeons must always be prepared for unexpected oncological findings during a laparotomy for acute pain.

Distinguishing Acute Adnexal Emergencies: Torsion vs. Rupture

Adnexal torsion and tumor rupture are both critical surgical emergencies that share overlapping clinical features. Torsion typically involves the mechanical rotation of the ovary on its ligamentous pedicle, leading to vascular compromise and eventual ischemia. In contrast, tumor rupture results in the leakage of contents into the peritoneal cavity, which can cause severe chemical peritonitis or hemoperitoneum. Clinically, both conditions present with acute-onset pelvic pain, nausea, and vomiting. For instance, in this 29-year-old patient, the clinical picture was almost identical to a classic torsion case. Furthermore, imaging modalities like ultrasound and CT may show a large adnexal mass and free fluid in both conditions. However, a ruptured teratoma often displays specific features such as the presence of fat or calcified components within the peritoneal fluid. Specifically, the \"tip of the iceberg\" sign on ultrasound can indicate a teratoma, but a rupture may obscure these classic findings. Moreover, the presence of internal solid components or irregular vascular projections should always raise suspicion for malignancy rather than a simple torsion of a benign cyst. Consequently, clinicians must maintain a broad differential diagnosis to ensure they do not overlook malignant indicators during the initial diagnostic workup. Prompt surgical intervention remains the gold standard for management.

Precision in Immature Ovarian Teratoma Management

Successful **immature ovarian teratoma management** hinges on the delicate balance between oncological safety and the preservation of reproductive function. Because these tumors frequently affect young women, fertility-sparing surgery is the standard of care for early-stage disease. This approach typically involves a unilateral salpingo-oophorectomy and complete surgical staging to rule out occult spread. In the reported case, the initial emergency laparotomy was followed by a comprehensive multidisciplinary review to determine the need for further intervention. This review is essential because even if the contralateral ovary appears normal, microscopic spread must be definitively ruled out. Additionally, the rupture of the mass (Stage IC2) significantly increases the risk of peritoneal seeding and recurrence. Therefore, adjuvant therapy becomes a critical component of the treatment plan. Specifically, the BEP regimen—comprising Bleomycin, Etoposide, and Cisplatin—is highly effective for malignant germ cell tumors. Furthermore, clinicians must monitor tumor markers like alpha-fetoprotein (AFP) and lactate dehydrogenase (LDH) throughout the treatment course. Postoperative AFP levels, which were 90.5 ng/ml in this patient, serve as a baseline for monitoring treatment response. Overall, the management strategy must be tailored to the specific grade and stage of the tumor to optimize the patient’s long-term prognosis.

Pathological Insights and Grading Significance

Pathological grading is the single most important prognostic factor for immature teratomas. Unlike most epithelial ovarian cancers, where the stage dictates the prognosis, the histological grade of the immature tissue determines the aggressiveness of this disease. Specifically, the Norris grading system evaluates the amount of immature neuroectodermal tissue present across the specimen. Grade 1 tumors have minimal immature elements and generally carry a favorable prognosis. However, Grade 3 tumors, like the one seen in this 29-year-old patient, contain significant amounts of primitive neuroepithelium. Furthermore, the coexistence of mature and immature components can be deceptive during initial inspection. In this case, 75% of the mass was mature, yet the remaining 25% of high-grade immature tissue dictated the malignant classification. Consequently, meticulous sampling of the entire surgical specimen is absolutely necessary. Pathologists must examine multiple sections to avoid under-grading the tumor and missing aggressive components. Moreover, the presence of somatic transformation—where components like neuroectodermal tissue become malignant—can further complicate the diagnosis. Therefore, a comprehensive histopathological review is indispensable for guiding the clinical team. This case underscores that even when a mass appears largely mature, the presence of high-grade elements fundamentally changes the clinical trajectory.

Therapeutic Strategy: Completion Surgery and BEP

Once a high-grade immature teratoma is confirmed, the therapeutic strategy shifts towards eliminating any residual disease. For FIGO Stage IC2, the risk of recurrence is significantly higher due to the prior rupture and peritoneal exposure. Consequently, the multidisciplinary team recommended completion surgery followed by aggressive adjuvant chemotherapy. The BEP protocol is the global gold standard for treating malignant germ cell tumors in both adult and pediatric populations. Specifically, it involves 3 to 4 cycles of chemotherapy, which has resulted in remarkably high cure rates worldwide. Furthermore, while chemotherapy can have long-term side effects, modern protocols are designed to minimize toxicity while maintaining peak efficacy. For instance, bleomycin-induced pulmonary toxicity is a known concern, requiring careful monitoring of lung function. Additionally, etoposide and cisplatin carry risks of bone marrow suppression and nephrotoxicity, respectively. However, the benefits of preventing recurrence in a Grade 3 tumor far outweigh these potential risks. Most young patients can resume normal menstrual cycles and maintain fertility after completing this regimen. Therefore, the combination of thorough surgical staging and platinum-based chemotherapy remains the cornerstone of modern management for high-grade immature ovarian teratomas. Persistent follow-up with serial tumor markers is essential to catch any early recurrence.

How does a ruptured teratoma impact FIGO staging compared to an intact one?

A ruptured ovarian teratoma significantly changes the FIGO stage and the subsequent treatment plan. While an intact tumor limited to the ovary is typically Stage IA, a rupture before or during surgery elevates it to Stage IC. Specifically, a rupture during surgery is Stage IC1, while a preoperative rupture is Stage IC2. This elevation is critical because it reflects the higher risk of peritoneal seeding. Consequently, adjuvant chemotherapy is mandatory for Stage IC2, regardless of the tumor grade, to address potential microscopic spread.

Why is alpha-fetoprotein (AFP) used as a marker for mixed ovarian teratomas?

Alpha-fetoprotein (AFP) serves as a vital biochemical marker for specific germ cell components within an ovarian mass. While pure mature teratomas do not typically secrete AFP, immature elements or associated yolk sac components often do. In this case, the postoperative AFP was 90.5 ng/ml, which helped confirm the presence of active malignant tissue. Furthermore, monitoring AFP levels during and after treatment allows clinicians to assess the efficacy of chemotherapy and detect early signs of recurrence. It is a highly sensitive indicator of disease burden.

What are the fertility implications of adjuvant chemotherapy for ovarian teratomas?

Adjuvant chemotherapy, specifically the BEP regimen, is generally well-tolerated with respect to reproductive health. Unlike some older chemotherapy protocols, platinum-based regimens like BEP often allow for the preservation of ovarian function in young women. Most patients regain regular menstrual cycles and retain their childbearing potential after completing their treatment. However, the risk depends on the baseline ovarian reserve and the intensity of the treatment. Therefore, clinicians should discuss fertility preservation options, such as oocyte cryopreservation, before starting chemotherapy if the clinical timeline permits.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Ashafaq M et al. Ruptured grade 3 mixed ovarian teratoma mimicking acute ovarian torsion: a case report. J Surg Case Rep. 2026 Jul undefined. doi: 10.1093/jscr/rjag468. PMID: 42436886.

Labdellaoui S et al. Immature Ovarian Teratoma: Case Report and Review of Literature. Scholars Journal of Medical Case Reports. 2024; 12(5): 699-704.

Alwazzan AB et al. Immature Teratoma: Diagnosis and Management—A Review of the Literature. MDPI - Diagnostics. 2023; 13(9): 1595.